Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (7)
Referred to the House Committee on Financial Services.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · third_quarter · Disaster Planning/Emergencies
General issues related to emergency planning and global catastrophic risk management. FORCE Act (H.R.3561). CLEAR (Committee Leadership and Enhanced Accountability for Resilience) Defense Production Act of 2025 (H.R.3542). National Defense Authorization Act for Fiscal Year 2026 (P.L. 119-60) implementation. Issues related to the National Defense Authorization Act for Fiscal Year 2027 (H.R.8800 / S. 4784). Issues related to the reauthorization of the Defense Production Act (DPA) for Fiscal Year 2027, including H.R.7688, the DPA Modernization Act of 2026.
Client expense: Not reported · Firm income: $10,000
Government targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE
2026 · third_quarter · Defense
FORCE Act (H.R.3561). CLEAR (Committee Leadership and Enhanced Accountability for Resilience) Defense Production Act of 2025 (H.R.3542). National Defense Authorization Act for Fiscal Year 2026 (P.L. 119-60) implementation. Issues related to the National Defense Authorization Act for Fiscal Year 2027 (H.R.8800 / S. 4784). Issues related to the reauthorization of the Defense Production Act (DPA) for Fiscal Year 2027, including H.R.7688, the DPA Modernization Act of 2026.
Client expense: Not reported · Firm income: $10,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE
2026 · second_quarter · Defense
FORCE Act (H.R.3561). CLEAR (Committee Leadership and Enhanced Accountability for Resilience) Defense Production Act of 2025 (H.R.3542). National Defense Authorization Act for Fiscal Year 2026 (P.L. 119-60) implementation. Issues related to the National Defense Authorization Act for Fiscal Year 2027 (H.R.8800 / S. 4784). Issues related to the reauthorization of the Defense Production Act (DPA) for Fiscal Year 2027, including H.R.7688, the DPA Modernization Act of 2026.
Client expense: Not reported · Firm income: $30,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE
2026 · second_quarter · Disaster Planning/Emergencies
General issues related to emergency planning and global catastrophic risk management. FORCE Act (H.R.3561). CLEAR (Committee Leadership and Enhanced Accountability for Resilience) Defense Production Act of 2025 (H.R.3542). National Defense Authorization Act for Fiscal Year 2026 (P.L. 119-60) implementation. Issues related to the National Defense Authorization Act for Fiscal Year 2027 (H.R.8800 / S. 4784). Issues related to the reauthorization of the Defense Production Act (DPA) for Fiscal Year 2027, including H.R.7688, the DPA Modernization Act of 2026. Issues related to the FY27 appropriations process, including Homeland Security appropriations legislation (H.R.9310).
Client expense: Not reported · Firm income: $30,000
Government targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE
2026 · first_quarter · Disaster Planning/Emergencies
General issues related to emergency planning and global catastrophic risk management. FORCE Act (H.R.3561). CLEAR (Committee Leadership and Enhanced Accountability for Resilience) Defense Production Act of 2025 (H.R.3542). National Defense Authorization Act for Fiscal Year 2026 (P.L. 119-60) implementation. Issues related to the reauthorization of the Defense Production Act (DPA) for Fiscal Year 2027, including H.R.7688, the DPA Modernization Act of 2026. Issues related to the FY26 Homeland Security Appropriations process.
Client expense: Not reported · Firm income: $30,000
Government targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Defense
FORCE Act (H.R.3561). CLEAR (Committee Leadership and Enhanced Accountability for Resilience) Defense Production Act of 2025 (H.R.3542). National Defense Authorization Act for Fiscal Year 2026 (P.L. 119-60) implementation. Issues related to the reauthorization of the Defense Production Act (DPA) for Fiscal Year 2027, including H.R.7688, the DPA Modernization Act of 2026.
Client expense: Not reported · Firm income: $30,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Defense
FORCE Act (H.R.3561). CLEAR (Committee Leadership and Enhanced Accountability for Resilience) Defense Production Act of 2025 (H.R.3542). National Defense Authorization Act for Fiscal Year 2026 (P.L. 119-60) implementation. Issues related to the reauthorization of the Defense Production Act (DPA) for Fiscal Year 2027, including H.R.7688, the DPA Modernization Act of 2026.
Client expense: $40,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Defense
Reauthorization of the Defense Production Act (DPA) of 1950 (P.L. 81-774, 50 U.S.C. 4501 et seq.) as well as the inclusion in the reauthorization bill of the text of the FORCE Act H.R.3561 and the CLEAR Act H.R.3542 in NDAA.
Client expense: $45,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Disaster Planning/Emergencies
Reauthorization of The Defense Production Act (DPA) of 1950 (P.L. 81-774, 50 U.S.C. 4501 et seq.) as well as the inclusion in the reauthorization bill of the text of the FORCE Act H.R.3561 and the CLEAR Act H.R.3542.
Client expense: $45,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Disaster Planning/Emergencies
General issues related to emergency planning and global catastrophic risk management. FORCE Act (H.R.3561). CLEAR (Committee Leadership and Enhanced Accountability for Resilience) Defense Production Act of 2025 (H.R.3542). Issues related to the reauthorization of the Defense Production Act (DPA). National Defense Authorization Act for Fiscal Year 2026 (P.L. 119-60).
Client expense: Not reported · Firm income: $30,000
Government targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
2025 · fourth_quarter · Defense
Issues related to the reauthorization of the Defense Production Act (DPA). FORCE Act (H.R.3561). CLEAR (Committee Leadership and Enhanced Accountability for Resilience) Defense Production Act of 2025 (H.R.3542). National Defense Authorization Act for Fiscal Year 2026 (P.L. 119-60).
Client expense: Not reported · Firm income: $30,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Disaster Planning/Emergencies
General issues related to emergency planning and global catastrophic risk management. FORCE Act (H.R.H.R.3561). CLEAR (Committee Leadership and Enhanced Accountability for Resilience) Defense Production Act of 2025 (H.R.3542). Issues related to the reauthorization of the Defense Production Act (DPA).
Client expense: Not reported · Firm income: $30,000
Government targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
2025 · third_quarter · Defense
Issues related to the reauthorization of the Defense Production Act (DPA). FORCE Act (H.R.H.R.3561). CLEAR (Committee Leadership and Enhanced Accountability for Resilience) Defense Production Act of 2025 (H.R.3542).
Client expense: Not reported · Firm income: $30,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Defense
Reauthorization of The Defense Production Act (DPA) of 1950 (P.L. 81-774, 50 U.S.C. 4501 et seq.) as well as the inclusion in the reauthorization bill of the text of the FORCE Act H.R.3561 and the CLEAR Act H.R.3542. Issues of Cyber Security and Weapons of Mass Destruction in the National Defense Authorization Act for FY 2026
Client expense: $40,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Disaster Planning/Emergencies
Reauthorization of The Defense Production Act (DPA) of 1950 (P.L. 81-774, 50 U.S.C. 4501 et seq.) as well as the inclusion in the reauthorization bill of the text of the FORCE Act H.R.3561 and the CLEAR Act H.R.3542.
Client expense: $40,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Disaster Planning/Emergencies
General issues related to emergency planning and global catastrophic risk management. FORCE Act (H.R.H.R.3561). CLEAR (Committee Leadership and Enhanced Accountability for Resilience) Defense Production Act of 2025 (H.R.3542). General issues related to the Defense Production Act (DPA).
Client expense: Not reported · Firm income: $30,000
Government targets: Defense, Dept of (DOD), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
2025 · second_quarter · Pharmacy
Issues related to pharmacy services, Pharmacy Benefit Managers Reform HR 3561/S 1038/S 1339/S 2052.
Client expense: $740,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2025 · second_quarter · Health Issues
- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Import of biological specimens for testing in a clinical laboratory
Client expense: $80,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Defense
Reauthorization of The Defense Production Act (DPA) of 1950 (P.L. 81-774, 50 U.S.C. 4501 et seq.) as well as the inclusion in the reauthorization bill of the text of the FORCE Act H.R.3561 and the CLEAR Act H.R.3542. "Inclusion of guidelines in the FY2026 National Defense Authorization Act on artificial intelligence-enhanced capabilities that may aid in the production of weapons of mass destruction"
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Disaster Planning/Emergencies
Reauthorization of The Defense Production Act (DPA) of 1950 (P.L. 81-774, 50 U.S.C. 4501 et seq.) as well as the inclusion in the reauthorization bill of the text of the FORCE Act H.R.3561 and the CLEAR Act H.R.3542.
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Health Issues
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act; H.R.5376 The Inflation Reduction Act.
Client expense: $1,220,000 · Firm income: Not reported
2025 · second_quarter · Health Issues
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484
Client expense: Not reported · Firm income: Not reported
2025 · second_quarter · Medicare/Medicaid
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484
Client expense: Not reported · Firm income: Not reported
2025 · second_quarter · Pharmacy
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484
Client expense: Not reported · Firm income: Not reported
2025 · second_quarter · Taxation/Internal Revenue Code
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484
Client expense: Not reported · Firm income: Not reported
2025 · second_quarter · Tariff (miscellaneous tariff bills)
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484
Client expense: Not reported · Firm income: Not reported
2025 · first_quarter · Health Issues
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act.
Client expense: $1,220,000 · Firm income: Not reported
2025 · first_quarter · Health Issues
Legislation affecting the regulation of private equity, including H.R. 3262, H.R. 3561, and other proposals related to equitable treatment of private equity in health care, private equity ownership with healthcare entities
Client expense: $710,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE